The FDA has approved a first‑in‑human study by Life Biosciences to test a reprogramming gene therapy aimed at reversing cellular aging mechanisms. The initial trial will enroll a small cohort of glaucoma patients; investigators will inject viral vectors carrying three reprogramming genes into one eye per patient, with gene expression controlled by a doxycycline‑inducible switch to limit exposure. The program—backed in part by cofounder David Sinclair—targets epigenetic reprogramming, a controversial approach that has shown rejuvenation potential in animals but raised safety concerns including tumorigenesis. The FDA clearance marks a major inflection point for aging‑biology therapeutics and will be watched closely for safety and biomarkers of epigenetic change.